menu
    • menu

    Company profile for Gannex Pharma

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 2019, Gannex, a wholly-owned company of Ascletis Pharma Inc. (1672.HK), is dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets — FASN, THR-β and FXR — and three combination therapies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Gannex PharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    New York, United States
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.gannexpharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Gannex Presents Positive ASC41 Phase 2 MASH Data At EASL 2024
    Gannex Presents Positive ASC41 Phase 2 MASH Data At EASL 2024

    10 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/gannex-announces-poster-presentation-of-positive-interim-12-week-results-from-phase-ii-clinical-trial-of-asc41-in-patients-with-biopsy-confirmed-mash-at-easl-congress-2024-302168053.html

    PR NEWSWIRE
    10 Jun 2024
    Share Share
    Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
    Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

    22 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/gannexs-strategic-partner-sagimet-biosciences-announces-positive-topline-results-from-phase-2b-fascinate-2-clinical-trial-of-denifanstat-in-biopsy-confirmed-f2f3-nash-302041397.html

    PR NEWSWIRE
    22 Jan 2024
    Share Share
    Gannex Announces Positive Results from Phase II Trial of Once-Daily ASC41 Tablet
    Gannex Announces Positive Results from Phase II Trial of Once-Daily ASC41 Tablet

    02 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/gannex-announces-positive-interim-results-from-52-week-phase-ii-clinical-trial-of-once-daily-asc41-tablet-in-patients-with-biopsy-confirmed-non-alcoholic-steatohepatitis-302024444.html

    PR NEWSWIRE
    02 Jan 2024
    Share Share
    Gannex posts data on NASH asset at center of trade secret row
    Gannex posts data on NASH asset at center of trade secret row

    02 Jan 2024

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/gannex-posts-midphase-data-nash-asset-center-trade-secret-row

    Nick Paul Taylor FIERCE BIOTECH
    02 Jan 2024
    Share Share
    Ascletis’ Gannex reports positive interim PhII NASH data
    Ascletis’ Gannex reports positive interim PhII NASH data

    02 Jan 2024

    // Ayisha Sharma ENDPTS

    https://endpts.com/ascletis-gannex-reports-positive-interim-phii-nash-data-after-scrapping-previous-mid-stage-rd-plans/

    Ayisha Sharma ENDPTS
    02 Jan 2024
    Share Share
    Gannex Published Phase I Data of ASC42
    Gannex Published Phase I Data of ASC42

    05 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/gannex-published-phase-i-data-of-asc42-a-novel-farnesoid-x-receptor-agonist-on-the-journal-drugs-in-rd-301978015.html

    PR NEWSWIRE
    05 Nov 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search